Zhifeng Cheng

ITER — France

Medicine · Health Sciences

15h-index969citations85works9.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(27), Metabolism, Diabetes, and Cancer(21), Pharmacology and Obesity Treatment(10), Diabetic Foot Ulcer Assessment and Management(7), Medicine and Dermatology Studies History(7)

Publications85 total

Comparison of clinical efficacy and facet joint invasiveness between unilateral biportal endoscopic and percutaneous endoscopic lumbar discectomy treatment of calcified lumbar disc herniation: a retrospective analysis
2025Open Access
Study on fluid-structure interaction of closed-type saddle membrane structure based on PIV technology
Engineering Structures·2025
A phase III clinical trial of monthly minodronate in the treatment of Chinese postmenopausal women with osteoporosis
Acta Pharmacologica Sinica·2025Open Access
Development and Application of Full-Length Lancing Technology of Steam Generator Secondary Side
2025
Design and Analysis of an Automated Video Inspection Robot for Tube Bundle Corridor in the Center of the First Support Plate of a Nuclear Power Steam Generator
2025
Clinical Practice Consensus Statement 2025: Management of Hyperuricemia and Gout in Adolescents
International Journal of Rheumatic Diseases·2025· 2 citedOpen Access
2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients
International Journal of Rheumatic Diseases·2025· 5 citedOpen Access
2001-LB: Symphony 1—A Randomized, Placebo-Controlled Phase 3 Study of Berberine Ursodeoxycholate as Monotherapy in Patients with Type 2 Diabetes
Diabetes·2025
752-P: Efficacy and Safety of Bofanglutide (GZR18), a Biweekly GLP-1RA, Compared with Semaglutide in Chinese Patients with T2D
Diabetes·2025
306-OR: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)
Diabetes·2025· 1 cited
807-P: Comparable Glycemic Control of Once-Weekly Insulin GZR4 Relative to Once-Daily Insulin Degludec in Insulin-Naïve Chinese Subjects with T2D
Diabetes·2025
839-P: Efficacy and Safety of HDG1901 vs. Ozempic in Patients with Type 2 Diabetes (T2D)—A Randomized, Open-Label, Bioequivalence Phase 3 Trial
Diabetes·2025
808-P: Superior Glycemic Control Achieved with Once-Weekly Insulin GZR4 Compared with Once-Daily Insulin Degludec in Insulin-Treated Chinese Subjects with T2D
Diabetes·2025
Performance Validation of J-TEXT X-ray imaging crystal spectrometer
2025
Efficacy and Safety of Dulaglutide Biosimilar <scp>LY05008</scp> Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open‐Label, Active Comparator Study
Journal of Diabetes·2025· 1 citedOpen Access
Study on the Origin and Development of Song and Tang Dynasty Huangshan Songkou Kiln
International Journal of Education and Humanities·2025Open Access
A biweekly <scp>DPP</scp> ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial
Diabetes Obesity and Metabolism·2024· 2 cited
Author response for "A biweekly &lt;scp&gt;DPP&lt;/scp&gt;‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial"
2024
GABA Analogue HSK16149 in Chinese Patients With Diabetic Peripheral Neuropathic Pain
JAMA Network Open·2024· 13 citedOpen Access
Global, regional, and national burden of ischemic stroke, 1990–2021: an analysis of data from the global burden of disease study 2021
EClinicalMedicine·2024· 242 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Hongwei� Jiang(6), Fang Bian(6), Jiajun Zhao(5), Qingsong Zhao(5), Xingwu Ran(4), Linong Ji(4), Jinmei Xu(4), Jianhua Ma(4), Shuguang Pang(4), Jianhua Ma(3), Dexue Liu(3), Nan Xia(3), Qingju Li(3), Shen Qu(3), Ping Li(3), Liujun Fu(3), Weiping Lu(3), Junhang Tian(3), Fangqiong Li(3), Xianyou Ji(3)